ArticleBMC infectious diseases2026
Enhancing therapy monitoring and effectiveness for HIV patients in China's border regions through a healthcare consortium: an interrupted time series analysis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHIV/AIDS remains a significant global health challenge, particularly in economically disadvantaged and underserved regions. Inequities in access to timely HIV diagnosis, treatment, and prevention services hinder progress in controlling the epidemic. Border counties of southwestern China face additional structural barriers including cross-border population movement, fragmented service delivery across mountainous terrain, and limited specialised workforce.
objectiveThis study evaluates the contribution of a regional healthcare consortium model, established in May 2020 in M City, Yunnan Province, to improving therapy monitoring and effectiveness for people living with HIV.
methodsWe conducted a retrospective single-site study using monthly aggregate programme data from January 2019 to July 2024. Indicators followed the WHO Consolidated Strategic Information Guidelines and the UNAIDS 95-95-95 framework, and included viral load (VL) testing rates, antiretroviral therapy (ART) coverage, and trimethoprim-sulfamethoxazole (SMZ) prophylaxis. Pre-intervention covered January 2019 to May 2020 and post-intervention covered June 2020 to July 2024. Descriptive statistics were complemented by an Interrupted Time Series (ITS) segmented regression analysis with Newey-West standard errors. Normality was tested with the Shapiro-Wilk statistic and non-parametric tests were used where appropriate. Multiple testing was controlled with the Benjamini-Hochberg false discovery rate procedure. Sensitivity analyses excluded peak COVID-19 disruption months and adjusted for the 2022 national HIV treatment guideline update. The study followed STROBE reporting standards.
findingsFollowing implementation of the consortium, the monthly number of newly enrolled ART patients increased by 69.8%, the VL test completion rate by 20.6% points (from 74.3% to 93.6%), the ART coverage rate by 7.2% points (from 85.9% to 92.6%), and the SMZ usage rate by 7.6% points (from 91.4% to 98.9%). ITS analysis showed sustained post-reform improvements in ART coverage rate (β
interpretationIn this single border city, the regional consortium was associated with substantial improvements in HIV care continuum indicators. The findings should be interpreted as evidence of the consortium's contribution rather than sole attribution, given the absence of a contemporaneous control. The model offers a candidate framework for HIV care integration in resource-constrained border counties of southwestern China and other comparable settings, although external validation through multi-site or controlled designs is required before broader generalisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.